Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176241 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer
A Phase 1 study, sponsored by Susanne Arnold.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00176241 is a Phase 1 study that was terminated before completion, run by Susanne Arnold. The registered enrollment target is 7 participants.
The verdict
NCT00176241, a Phase 1 study, was terminated before completion, sponsored by Susanne Arnold.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study seeks to establish the safety of gemcitabine, paclitaxel and low-dose radiation in recurrent, metastatic head and neck cancer through a two-stage dose escalation study, first with Gemcitabine dose escalation and then with low-dose radiation escalation. Treatment Schedule Treatment will be administered on an inpatient or outpatient basis. * Gemcitabine:2000 to 3000mg/m2 IV (in the vein) on days 1 and 15 every 28 days over 30-60 minutes. * Paclitaxel: 150 mg/m2 IV(in the vein)on days 1 and 15 every 28 days over 60 minutes. * Low Dose Radiation: 50-80 cGy twice daily on days 1, 2, 15, \& 16 every 28 days at least 4 hours apart.
Interventions
- DRUG paclitaxel
- DRUG gemcitabine
- RADIATION radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176241
The ClinicalTrials.gov registry entry for NCT00176241 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Susanne Arnold, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00176241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176241 about?
NCT00176241 is a clinical study titled "Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer". This study seeks to establish the safety of gemcitabine, paclitaxel and low-dose radiation in recurrent, metastatic head and neck cancer through a two-stage dose escalation study, first with Gemcitabine dose escalation and then with low-dose radiation escalation. Treatment Schedule Treatment will ...
What is the current status of trial NCT00176241?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2005-12. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00176241?
The interventions under investigation include: paclitaxel (DRUG), gemcitabine (DRUG), radiation (RADIATION).
Who is sponsoring clinical trial NCT00176241?
This trial is sponsored by Susanne Arnold, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.